VBIO · Valion Bio, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“Based on the Company’s current cash levels and burn rate, amongst other things, the Company believes its cash and financial resources may be insufficient to meet the Company’s anticipated needs for the twelve months following the date of issuance of the financial statements for the six months ended June 30, 2026, included elsewhere in this Report, which raises substantial doubt about the Company’s ability to continue as a going concern within one year from the issuance date of the financial statements.”View the 10-Q filed Aug 14, 2026
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| $482K | — | $780K | $1.18M | $1.84M | $1.26M | |
| — | — | $6000 | $1000 | $2000 | -$1.82M | |
| $762K | — | $778K | $889K | $1.54M | $1.3M | |
| -$280K | — | $2000 | $287K | $299K | -$38K | |
| — | — | 0.26% | 24.4% | 16.25% | -3.02% | |
| $6.7M | $3.13M | $1.31M | $1.66M | $1.73M | $878K | |
| $1.26M | — | $1.19M | $2.13M | $2.79M | $1.79M | |
| $3.68M | — | $3.16M | $4.75M | $5.88M | $2.93M | |
| — | $4.77M | $3.16M | — | — | — | |
| $3000 | — | $3000 | $8000 | $10K | — | |
| $16.9M | $7.9M | $4.48M | $8.53M | $10.4M | $5.6M | |
| -$16.9M | -$7.9M | -$4.48M | -$8.25M | -$10.1M | -$5.63M | |
| — | — | -573.85% | -701.11% | -548.8% | -448.13% | |
| -$4.78M | — | -$4.47M | -$8.24M | -$10.09M | — | |
| — | $146K | $0 | — | — | — | |
| $51K | $23K | $6000 | — | — | — | |
| -$1.33M | -$95K | $6000 | $1000 | $2000 | -$2.86M | |
| — | — | — | -$8.24M | -$10.1M | — | |
| — | $0 | $0 | — | — | — | |
| -$18.75M | -$8.88M | -$5.66M | -$8.24M | -$10.1M | -$8.49M | |
| — | — | -725% | -701.02% | -548.7% | -675.74% | |
| USD/shares | -$7.53 | -$7.84 | -$19.68 | -$176.80 | -$1,773.44 | -$4,131.00 |
| USD/shares | -$1.87 | — | -$19.68 | -$176.80 | -$1,773.44 | -$4,131.00 |
| shares | — | 1.16M | 287.37K | 46.65K | 5692.8235 | 2054.8629 |
| shares | — | — | 287.37K | 46.65K | 5692.8235 | 2054.8629 |
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 128 similar-size Biotechnology companies (of 518 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Shipping And Handling | $1,000 | $3,000 | $3,000 | $5,000 |